Vivesto AB (“Vivesto” or the “Company”) hereby announces that the acting CEO of the Company, Christer Nordstedt, has resigned from his position in order to assume a new role outside of the Company.
The process of recruiting a permanent CEO has been accelerated. Christer Nordstedt will continue in his current role until 30 November 2022 and will thereafter remain as senior advisor to Vivesto on a consultancy basis.
Christer Nordstedt has been acting CEO since 21 July 2022.
Peter Zonabend, Chairman of the Board of Vivesto, said: “We would like to thank Christer for his efforts during his time as acting CEO of Vivesto, and we are pleased that Christer, with his extensive knowledge and experience in R&D, will remain within the Company in an advisory role.”
For more information:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 18-50 54 40
About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.